Linear Clinical Research

Futó vizsgálatok

• Toboroz

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· 1/2. fázis· XYone Therapeutics, Inc· Forrás

• Toboroz

  A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

  NCT07545122· 1. fázis· Context Therapeutics Inc.· Forrás

• Toboroz

  TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

  NCT07713732· 1. fázis· Treeline Biosciences, Inc.· Forrás

• Toboroz

  A Study of ARC-02 in B-cell NHL

  NCT07691606· 1. fázis· Taiho Oncology, Inc.· Forrás

• Toboroz

  Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders

  NCT07529951· 1. fázis· Eilean Therapeutics· Forrás

• Toboroz

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· 1. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· 1. fázis· Incyte Corporation· Forrás

• Toboroz

  Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

  NCT07249905· 1/2. fázis· ModeX Therapeutics, An OPKO Health Company· Forrás

• Toboroz

  A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

  NCT07532655· 1. fázis· CSPC ZhongQi Pharmaceutical Technology Co., Ltd.· Forrás

• Toboroz

  Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

  NCT07285122· 1. fázis· Atisama Therapeutics· Forrás

• Toboroz

  Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT07435038· 1/2. fázis· Betta Pharmaceuticals Co., Ltd.· Forrás

• Toboroz

  Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

  NCT07334119· 1. fázis· Myeloid Therapeutics· Forrás

• Toboroz

  A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

  NCT07244705· 1/2. fázis· Anbogen Therapeutics, Inc.· Forrás

• Toboroz

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· 1. fázis· Incyte Corporation· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· 3. fázis· BeOne Medicines· Forrás

• Toboroz

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· 3. fázis· Amgen· Forrás

• Toboroz

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· 2. fázis· Amgen· Forrás

• Fut, nem toboroz

  A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

  NCT06830850· 1. fázis· Atridia Pty Ltd.· Forrás

• Toboroz

  A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

  NCT06944925· 1. fázis· Bambusa Therapeutics· Forrás

• Toboroz

  A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

  NCT06917742· 1. fázis· Capstan Therapeutics· Forrás

• Toboroz

  BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

  NCT06756932· 1. fázis· BeOne Medicines· Forrás

• Toboroz

  A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  NCT06789172· 1. fázis· Epkin· Forrás

• Toboroz

  A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  NCT06697184· 1/2. fázis· BeOne Medicines· Forrás

• Meghívásos bevonás

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· 1. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· 2. fázis· Coherus Oncology, Inc.· Forrás

• Toboroz

  ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

  NCT06597721· 1. fázis· Adcendo ApS· Forrás

• Toboroz

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· 2. fázis· TORL Biotherapeutics, LLC· Forrás

• Toboroz

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· 3. fázis· Corvus Pharmaceuticals, Inc.· Forrás

• Toboroz

  A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

  NCT06478693· 1. fázis· Myeloid Therapeutics· Forrás

• Toboroz

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  NCT06465069· 1. fázis· Eli Lilly and Company· Forrás

• Toboroz

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· 3. fázis· Immunocore Ltd· Forrás

• Toboroz

  Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

  NCT06366789· 1. fázis· Lomond Therapeutics Holdings, Inc.· Forrás

• Toboroz

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· 1. fázis· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Forrás

• Fut, nem toboroz

  Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

  NCT06205628· 1. fázis· ADARx Pharmaceuticals, Inc.· Forrás

• Toboroz

  A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  NCT06244771· 1/2. fázis· Frontier Medicines Corporation· Forrás

• Toboroz

  A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

  NCT05910827· 1/2. fázis· Hummingbird Bioscience· Forrás

• Toboroz

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· 1/2. fázis· Revolution Medicines, Inc.· Forrás

• Toboroz

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· 1. fázis· Incyte Corporation· Forrás

• Toboroz

  Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  NCT05862012· 1. fázis· Ichnos Sciences SA· Forrás

• Toboroz

  IKS014 in Advanced Solid Tumors That Express HER2

  NCT05872295· 1. fázis· Iksuda Therapeutics Ltd.· Forrás

• Fut, nem toboroz

  Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

  NCT05919537· 1. fázis· Hummingbird Bioscience· Forrás

• Toboroz

  IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

  NCT05365659· 1. fázis· Iksuda Therapeutics Ltd.· Forrás

• Fut, nem toboroz

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

  NCT05907304· 1. fázis· Erasca, Inc.· Forrás

• Toboroz

  Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

  NCT05969041· 1. fázis· Myeloid Therapeutics· Forrás

• Fut, nem toboroz

  Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

  NCT05878184· 1. fázis· Sana Biotechnology· Forrás

• Fut, nem toboroz

  ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

  NCT05650879· 1. fázis· Enliven Therapeutics· Forrás

• Fut, nem toboroz

  Study to Assess SLN124 in Patients With Polycythemia Vera

  NCT05499013· 1/2. fázis· Silence Therapeutics plc· Forrás

• Fut, nem toboroz

  Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

  NCT05544552· 1/2. fázis· Tyra Biosciences, Inc· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

  NCT05581004· 1. fázis· Genentech, Inc.· Forrás

Showing 50 of 68.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák14 toboroz
• Vastagbélrák9 toboroz
• Fej-nyaki daganatok5 toboroz
• Follikuláris limfóma5 toboroz
• Gyomor- és nyelőcsőrák5 toboroz
• Hasnyálmirigyrák5 toboroz
• Köpenysejtes limfóma5 toboroz
• Mieloproliferatív neopláziák5 toboroz
• Petefészekrák5 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)4 toboroz
• Krónikus limfoid leukémia (CLL)4 toboroz
• Prosztatarák4 toboroz
• Tripla negatív emlőrák4 toboroz
• Akut mieloid leukémia (AML)3 toboroz
• Máj- és epeúti rák3 toboroz
• Mielodiszplasztikus szindróma (MDS)3 toboroz
• Hodgkin-limfóma2 toboroz
• Hólyagrák2 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)2 toboroz
• Lupus (SLE)2 toboroz
• Méhnyakrák2 toboroz
• Méhtestrák2 toboroz
• Melanóma2 toboroz
• Mezotelióma2 toboroz
• Rheumatoid arthritis2 toboroz
• Szarkóma2 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Chronic rhinosinusitis with nasal polyps1 toboroz
• Elhízás1 toboroz
• Gyermekkori daganatok1 toboroz
• Koszorúér-betegség1 toboroz
• Krónikus mieloid leukémia (CML)1 toboroz
• Mielóma multiplex1 toboroz
• Neuroendokrin daganatok1 toboroz

Lezárt vizsgálatok

• Lezárult

  A Trial of HRS-1893 in Healthy Volunteers

  NCT07033455· Korai 1. fázis· Atridia Pty Ltd.· Forrás

• Toboroz

  A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

  NCT06808477· 1. fázis· Bambusa Therapeutics· Forrás

• Leállították

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· 1. fázis· BeOne Medicines· Forrás

• Lezárult

  A Study of TeriQ Patch in Healthy Adult Female Participants

  NCT06644040· 1. fázis· QuadMedicine· Forrás

• Lezárult

  Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers

  NCT06780124· 1. fázis· Eilean Therapeutics· Forrás

• Lezárult

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

  NCT06326060· 2. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· 1. fázis· Prelude Therapeutics Incorporated· Forrás

• Leállították

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· 1. fázis· BeOne Medicines· Forrás

• Lezárult

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· 2. fázis· GCP-Service International West GmbH· Forrás

• Lezárult

  Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

  NCT05425446· 1. fázis· Chugai Pharmaceutical· Forrás

• Leállították

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· 1. fázis· Nuvation Bio Inc.· Forrás

• Lezárult

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· 1. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

  NCT04670679· 1. fázis· Erasca, Inc.· Forrás

• Lezárult

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· 1. fázis· Janssen Research & Development, LLC· Forrás

• Leállították

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· 2. fázis· Elevation Oncology· Forrás

• Lezárult

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· 1. fázis· Incyte Corporation· Forrás

• Lezárult

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· 1/2. fázis· Elevar Therapeutics· Forrás

• Lezárult

  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

  NCT04109456· 1. fázis· InxMed (Shanghai) Co., Ltd.· Forrás

• Lezárult

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· 1. fázis· BeiGene· Forrás

• Lezárult

  To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

  NCT04052971· 1. fázis· Abion Inc· Forrás

• Lezárult

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· 1. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· 1/2. fázis· Loxo Oncology, Inc.· Forrás

• Lezárult

  A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

  NCT03331731· 2. fázis· Peter MacCallum Cancer Centre, Australia· Forrás

• Lezárult

  Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

  NCT03674567· 1/2. fázis· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Forrás